Connect your AI

ADMA Biologics ADMA Gain On Sale Of Investments

Segments

By segment

Plasma Collection Centers$7.98M—

ADMA Bio Manufacturing$0—

Other financials

Income statement

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

Market cap$2.02B-54.5%

Profitability

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:GainOnSaleOfInvestments.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's gain on sale of investments.

Connect your AI assistant and break it down by segment, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ADMA Biologics's gain on sale of investments?: ADMA Biologics (ADMA) reported gain on sale of investments of $7.98M in Q1 2026.